Abstract: A method and apparatus for the collection of physiological data from a patient is disclosed herein. An electrode assembly comprises an external label identifying an anatomical location and an electrode identifying circuitry that produces a signal indicative of the anatomical location to which the electrode assembly is to be attached. The electrode assembly transmits both the collected physiological signal and the identification signal to a data monitor for collection and processing physiological data.

Abstract: The present invention provides nucleosides of formula (1) and oligonucleotides comprising at least one nucleoside of formula (2): Another aspect of the invention relates to a method of inhibiting the expression of a gene in cell, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.

Abstract: This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.

Abstract: This invention relates to use of inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.

Abstract: In one embodiment of a networking module, a first block receives a serial digital media signal, and provides a parallel digital media signal based on the serial digital media signal. A second block, operative with the first block, stores the parallel digital media signal in a corresponding slot in an outgoing frame, and sends the outgoing frame in response to receiving an incoming frame.

Abstract: This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.

Abstract: The invention provides a method for the separation and purification of two or three cellular components selected from genomic DNA, RNA and proteins from a single biological sample. The method comprises generating an aqueous solution containing the cellular components by lysing cells with a lysis solution; contacting the aqueous solution with an ion exchanger for genomic DNA and RNA to bind to the ion exchanger; collecting the flow-through which contains unbound proteins; eluting RNA from the ion exchanger; and eluting DNA from the ion exchanger. For the purification of any two of the cellular components, one of the components is not collected. The invention also provides reagent kits for carrying out the methods.

Abstract: A method and apparatus for the collection of physiological data from a patient is disclosed herein. An electrode assembly comprises an external label identifying an anatomical location and an electrode identifying circuitry that produces a signal indicative of the anatomical location to which the electrode assembly is to be attached. The electrode assembly transmits both the collected physiological signal and the identification signal to a data monitor for collection and processing physiological data.

Abstract: In one embodiment of a networking module, a first block receives a serial digital media signal, and provides a parallel digital media signal based on the serial digital media signal. A second block, operative with the first block, stores the parallel digital media signal in a corresponding slot in an outgoing frame, and sends the outgoing frame in response to receiving an incoming frame.

Abstract: A method and apparatus for the collection of physiological data from a patient is disclosed herein. An electrode assembly comprises an external label identifying an anatomical location and an electrode identifying circuitry that produces a signal indicative of the anatomical location to which the electrode assembly is to be attached. The electrode assembly transmits both the collected physiological signal and the identification signal to a data monitor for collection and processing physiological data.

Abstract: Provided is a novel two step chromatographic purification process (load and elute) for the isolation of genomic DNA. In this method the sample is loaded on the column and the genomic DNA product is eluted directly without any intermediate wash steps. This is accomplished by utilizing a restricted access resin (i.e., lid beads), which is easy to prepare and comprised of two layers with different properties with non-functional surfaces on the outer layer. The inner layer is modified with functional groups that act as ion-exchangers. Small molecules such as RNA and proteins can enter the inner part of the resin and larger genomic DNA molecules will pass through the resin. RNA and proteins are captured in the inner layer of the restricted access resin while genomic DNA is readily eluted in the flow-through.

Abstract: Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.

Abstract: Systems and methods for steam turbine remote monitoring, calculating corrected efficiency, monitoring performance degradation, diagnosing and benchmarking are disclosed with an example turbine system including a turbine, a data acquisition device coupled to the turbine, the data acquisition device for collecting turbine data that includes performance parameters of the turbine and a central monitoring system coupled to the data acquisition device, the central monitoring system for receiving the collected turbine data and processing the turbine data to determine turbine performance.

Abstract: The invention provides a method for the separation and purification of two or three cellular components selected from genomic DNA, RNA and proteins from a single biological sample. The method comprises generating an aqueous solution containing the cellular components by lysing cells with a lysis solution; contacting the aqueous solution with an ion exchanger for genomic DNA and RNA to bind to the ion exchanger; collecting the flow-through which contains unbound proteins; eluting RNA from the ion exchanger; and eluting DNA from the ion exchanger. For the purification of any two of the cellular components, one of the components is not collected. The invention also provides reagent kits for carrying out the methods.

Abstract: Disclosed is a process for separating and/or purifying a nucleic acid by elution of the nucleic acid from anion exchange resins under conditions of high salt concentration and the presence in the eluant of an additive comprising guanidine, or a guanidine-like derivative. The process allows high recovery of nucleic acids from anion exchange resins without impairing the nucleic acid stability as compared with conventional ion exchange chromatographic procedures.

Abstract: The invention provides an improved method for the purification of nucleic acid molecules, which method comprises generating a cellular lysate containing the nucleic acid; contacting the lysate with an anion exchanger bound to a solid support matrix under conditions such that the anion exchanger binds the nucleic acid; followed by eluting the nucleic acid from the anion exchanger with an aqueous mobile phase comprising an elution solution; and desalting the eluted nucleic acid such that it is suitable for downstream applications. The improvement of the method includes providing the anion exchanger in a packed column, wherein the column is packed using a salt solution containing an antimicrobial agent. In addition, the salt solution has a salt concentration similar to that of the lysate, such that the column does not need equilibration prior to sample loading.

Abstract: The invention provides an improved method for the purification of nucleic acid molecules, which method comprises generating a cellular lysate containing the nucleic acid; contacting the lysate with an anion exchanger bound to a solid support matrix under conditions such that the anion exchanger binds the nucleic acid; followed by eluting the nucleic acid from the anion exchanger with an aqueous mobile phase comprising an elution solution; and desalting the eluted nucleic acid such that it is suitable for downstream applications. The improvement of the method includes adding in the elution solution a composition such that the pH of the aqueous mobile phase is between about pH 9 and about pH 13, wherein the presence of the composition in the elution solution provides an increase in nucleic acid recovery, as compared with the recovery in the absence of the composition.

Abstract: Lonidamine derivatives can be useful in methods of treating, inhibiting, and/or preventing polycystic kidney disease (PKD). Accordingly, lonidamine derivatives can be administered in a therapeutically effective amount for inhibiting, and/or preventing polycystic kidney disease (PKD) in the subject. This can include administering a therapeutically effective amount of the lonidamine derivatives for inhibiting CFTR and/or Hsp90 or biological pathway thereof. Also, the method can include administering the lonidamine derivatives in a therapeutically effective amount for inhibiting ErbB2, Src, Raf-1, B-Raf, MEK, Cdk4, NKCC1, or combinations thereof. For example, the therapeutically effective amount of the lonidamine derivatives can be configured so as to provide a concentration in or adjacent to a kidney cell of about 0.25 uM or more or less.

Abstract: Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.

Abstract: The method includes obtaining input data representative of a first parameter of a cryogenic medium in a cryogenic cooling system is provided. The method further includes calculating an expected value representative of a second parameter of the cryogenic medium in the cooling system via a predefined physics based model. A second input data representative of the second parameter of the cryogenic medium in the cooling system is estimated. The expected value is compared to the second input data and difference between the expected value and the second input data is correlated to statistical data to estimate a likelihood of cryogenic cooling system event.